Autoimmune Diseases Treatment Market Size & Growth Analysis to 2030

The global autoimmune diseases treatment market is expected to grow at the CAGR of 3.8% during 2020-2027. The global market is segmented on the basis of therapeutics and geography. The report on global autoimmune diseases treatment market (by therapeutics and geography) provides a detailed overview and predictive analysis of the market.

Market Insights:

Autoimmune disease is defined as functional instability caused to the immune system. This reaction takes place when an individual’s immune system defends itself by producing its autoantibodies against the healthy cells and tissues rather than infectious agents. Autoantibodies produced, cause pain, inflammation, and sometimes even organ damage. It is one of the top 10 leading causes of mortality in girls and women observed in all age groups up to 64 years of age. Traditionally available treatment options are chemical based drugs which including corticosteroids, immunosuppressants, and NSAIDs. In recent development, biological drugs are looked are preferred over chemical based drugs , due to fewer side-effects, target-specific activity, and high patient compliance compared to chemical-based drugs. With rising awareness about autoimmune disease, an increase in healthcare expenditure in both developed and developing countries are some of the driving factors for the growth of autoimmune disease treatment.

The global autoimmune disease treatment market report includes the study of various drug used for the treatment of disease and also pipeline analysis of upcoming potential drugs. Autoimmune disease is developed when one’s immune system starts attacking the healthy cells as a foreign element. There are around 80 types of autoimmune diseases and are characterized as immune system dysfunction, increased level of autoantibodies, inflammatory and mediatory cells, loss of tolerance to self-antigens that further leads to chronic inflammation. Thus the drugs in the pipeline comprise innovative properties and more target specific drugs.

Market Segment Insights:

On the basis of products, the global autoimmune diseases treatment market is majorly segmented into chemical-based drugs and biological drugs. Chemical drugs include immunosuppressant drugs, NSAIDs and corticosteroids. It also includes pipeline analysis of phased III drugs of most prevalent autoimmune diseases such as Hashimoto’s Thyroiditis, Type I Diabetes, Crohn’s Disease, Multiple Sclerosis, Rheumatoid Arthritis, Ankylosing Spondylitis, Systemic Lupus Erythematosus, and Psoriasis.

Global Autoimmune Diseases Treatment Market Segmentation:

By Therapeutics Type, 2018–2027 ($ Million)

• Overview
• Chemical-based Drugs
  • Immunosuppressant Drugs
  • NSAIDs
  • Corticosteroids
• Biological Drugs
• Pipeline Analysis
  • Projected sales of Phase III Drugs estimated till 2025, by Most Prevalent Autoimmune Diseases ($ Million)
    • Hashimoto’s Thyroiditis
    • Type I Diabetes
    • Crohn’s Disease
    • Multiple Sclerosis
    • Rheumatoid Arthritis
    • Ankylosing Spondylitis
    • Systemic Lupus Erythematosus
    • Psoriasis
  • Tabular Representation of Phase II and I Drugs

By Geography, 2018-2027 ($ Million)

• North America (U.S. & Canada)
• Europe (U.K., Germany & Rest of Europe)
• Asia Pacific (China, Japan, and Rest of APAC)
• Latin America (Brazil, Mexico and Rest of LATAM)
• Middle East and Africa (UAE, Saudi Arabia, South Africa)

Regional Insights:

Geographically, North America dominates the global autoimmune diseases treatment market in 2019. The main driver of the market in North America is rising prevalence of different forms of autoimmune disorders. According to the American Autoimmune Related Diseases Association (AARDA), around 50 million Americans suffer from autoimmune diseases and is one of the top ten leading causes of mortality in females (children and adults) in all age groups up to 64 years of age. Rapid growth is observed in Asia Pacific for the autoimmune diseases treatment market; due to improving healthcare structure, rising aging population and increasing health awareness.

Market Competition Assessment:

Key players in the global autoimmune diseases treatment market are Genentech Inc., Bayer AG, Merck & Co., Amgen Inc., Johnson & Johnson Limited, Abbott Laboratories, Eli Lilly and Company, GlaxoSmithKline Plc, F. Hoffmann-La Roche AG, Bristol Myers Squibb Company, and others.

List of Key Companies:

• Abbott Laboratories
• Amgen Inc.
• Bayer AG
• Bristol Myers Squibb Company
• Eli Lilly and Company
• Hoffmann-La Roche AG
• GlaxoSmithKline Plc
• Genentech Inc.
• Merck & Co.
• Johnson & Johnson Limited
• Others